Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2022 and 2023.
-
Busy address KBO
14 other companies have their registered office at the same address; threshold 10.
-
Legal situation KBO
Opening faillissement according to the CBE.
Financials
Financial year 2023
FOx Biosystems from Diepenbeek, company number BE0653744366, closed financial year 2023 with a result of € -2.8 million after tax. For that financial year FOx Biosystems recorded a gross margin of € -763,895 and equity of € 1.3 million. Compared with financial year 2022, the result moved from € -3.3 million to € -2.8 million. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 9, 2024.
€ 1.3 million
▼ 48% vs 2022
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -2.8 million
▲ 16 % less loss than in 2022
Profit after tax over the fiscal year.
€ 620,854
▼ 55% vs 2022
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -3.7 million.
People and assets in 2023
13.8
▲ 1.7 vs 2022
Average over the fiscal year, from the social balance sheet.
€ 1.4 million
▲ 22% vs 2022
€ 102,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 41,630
▲ € 34,588 vs 2022
Book value of vehicles, furniture and equipment.
Debts at end 2023
None
No bank loans on the last day of the fiscal year.
€ 444,948
▲ 38% vs 2022
Supplier invoices still open on the last day of the fiscal year.
€ 161,085
▲ 144% vs 2022
Taxes, VAT and social contributions still to pay.
| 2021 | 2022 | 2023 | Change 2022 → 2023 | |
|---|---|---|---|---|
| Gross margin | € -1,044,773 | € -1,459,409 | € -763,895 | ▲ € 695,513 |
| Profit after taxes | € -2,284,807 | € -3,337,486 | € -2,788,674 | ▲ € 548,812 |
| Equity | € 1,322,579 | € 2,475,533 | € 1,290,985 | ▼ 48% |
| Total debts | € 3,125,272 | € 530,890 | € 1,428,984 | ▲ 169% |
| Cash | € 2,405,587 | € 1,366,941 | € 620,854 | ▼ 55% |
| Retained profit | € -4,073,828 | € -7,411,313 | € -3,699,987 | ▲ € 3.7 million |
| Bank debt | € 2,652,776 | € 0 | € 0 | |
| Balance sheet total | € 4,447,851 | € 3,006,423 | € 2,719,968 | ▼ 10% |
| Employees (FTE) | 9 | 12.1 | 13.8 | ▲ 1.7 |
Key figures of FOx Biosystems, fiscal years 2021 to 2023, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2024 has not been filed yet; it was expected before 31 July 2025.
What happened to FOx Biosystems?
What happened at FOx Biosystems in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
FOx Biosystems is active according to the CBE. Legal situation: Opening faillissement.
- Heran Partners BV stepped down as director. NBB
- Bart Geers stepped down as director. NBB
- LRM Beheer BV stepped down as director. NBB
- Jeroen Lammertyn stepped down as director. NBB
- Jerry Williamson stepped down as director. NBB
- Mark Truesdale stepped down as director. NBB
- Filip Delport stepped down as director. NBB
- New annual accounts for financial year 2023: loss of € 2.8 million. Source: NBB ↗
In short
From € 2.3 million loss in 2021 to € 2.8 million loss in 2023.
Paid € 18,798 in corporate taxes since 2021.
Management
The stake of LIMBURGSE RECONVERSIE MAATSCHAPPIJ, Heran HealthTech Fund I comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
FOx BiosystemsThe shares are held by LIMBURGSE RECONVERSIE MAATSCHAPPIJ (33.9%) and Heran HealthTech Fund I (30.6%). It owns 100% of Fox Biosystems Ltd itself.
Directors
According to the 2023 annual accounts
Director · represented by Thomas van Elzakker
since 2020 · until 2023
Director · represented by Kathleen Vandersmissen
Also active at: Lynxcare Clinical Informatics, ASPECT ANALYTICS, Heran HealthTech Fund I, nuclivision, ImmuneSpec, AMARON, icometrix, ONTOFORCE
since 2020 · until 2030
since 2019 · until 2030
Director · represented by Dries Bauters
Also active at: H.W.P., Corda Campus, MIJNSCHADE EN BEMALING LIMBURGS MIJNGEBIED, be-DIVE, LRM Lease, RMW, CORDA CAMPUS 2.0, Mobietrain +33 more
since 2019 · until 2030
Jeroen Lammertyn
Director
since 2019 · until 2030
Jerry Williamson
Director
since 2024 · until 2030
Mark Truesdale
Director
since 2023 · until 2030
Filip Delport
Director
since 2019 · until 2030
Shareholders
Participations
Fox Biosystems Ltd
100%
Establishments
Establishment units
Physical locations of this company
Agoralaan Abis
3590 Diepenbeek
Bollebergen 2b
9052 Gent
Active since 13 February 2023
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 14 companies are registered at this address.
All companies at this address →Clinitude
€ 419,430 gross margin · 2025
Highstar Engineering
€ -52,153 gross margin · 2025
IDEA FAMILY
€ -1,811 gross margin · 2026
BIOKEY
€ -16,079 gross margin · 2026
BIOSTRAND
€ -3.7 million gross margin · 2026
+9 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0653.744.366
- VAT number
- BE 0653.744.366
- Registered office
- Agoralaan Abis, 3590 Diepenbeek
- Names & denominations
- FOx Biosystems
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Opening faillissement
- Start date
- 3 May 2016
- Peppol
- Not registered
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied
Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg
Activiteiten van adviesbureaus op het gebied van public relations en communicatie
Overige gespecialiseerde wetenschappelijke en technische activiteiten
Adviesbureaus op het gebied van public relations en communicatie